{
    "id": 21452,
    "fullName": "CDKN2B loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CDKN2B loss indicates loss of the CDKN2B gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1030,
        "geneSymbol": "CDKN2B",
        "terms": [
            "CDKN2B",
            "CDK4I",
            "INK4B",
            "MTS2",
            "P15",
            "p15INK4b",
            "TP15"
        ]
    },
    "variant": "loss",
    "createDate": "04/20/2016",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5881,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Falsodex (fulvestrant), Alpelisib (BYL719), and Kisqali (ribociclib) resulted in rapid tumor reduction in PDX models of breast cancer cells harboring ESR1 Y537S and concomitant loss of CDKN2A and CDKN2B (PMID: 27020857).",
            "molecularProfile": {
                "id": 21976,
                "profileName": "CDKN2A loss CDKN2B loss ESR1 Y537S"
            },
            "therapy": {
                "id": 2317,
                "therapyName": "Alpelisib + Fulvestrant + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5879,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alpelisib (BYL719) and Kisqali (ribociclib) resulted in tumor regression in patient-derived xenograft (PDX) models of estrogen-receptor positive breast cancer harboring ESR1 Y537S and loss of both CDKN2A and CDKN2B, with improved efficacy over either agent alone (PMID: 27020857).",
            "molecularProfile": {
                "id": 21976,
                "profileName": "CDKN2A loss CDKN2B loss ESR1 Y537S"
            },
            "therapy": {
                "id": 3969,
                "therapyName": "Alpelisib + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9355,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited tumor growth and improved survival in patient-derived intracranial xenografts models of RB-proficient glioblastoma harboring homozygous deletion of the CDKN2A and CDKN2B (PMID: 20354191).",
            "molecularProfile": {
                "id": 26829,
                "profileName": "CDKN2A loss CDKN2B loss RB1 pos"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4520,
                    "pubMedId": 20354191,
                    "title": "Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20354191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21975,
            "profileName": "CDKN2B loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21976,
            "profileName": "CDKN2A loss CDKN2B loss ESR1 Y537S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26829,
            "profileName": "CDKN2A loss CDKN2B loss RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}